



03-23-06

CASE ON/4-32586A

zfw

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV72727462545  
Express Mail Label Number

MARCH 22, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

OHTSURU ET AL.

INTERNATIONAL APPLICATION NO: PCT/IB03/01985

FILED: 23 MAY 2003

U.S. APPLICATION NO: 10/521,929

35 USC §371 DATE: 5 AUGUST 2005

FOR: 4-(4-METHYLPYPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE FOR TREATING ANAPLASTIC THYROID CANCER

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Oona A. Jackson  
Attorney for Applicants  
Reg. No. 48,152

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852

Date: 3/22/06

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32586A  
APPLICATION NO.  
10/521,929  
APPLICANT  
OHTSURU ET AL.  
FILING DATE  
AUGUST 5, 2005

Group



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	* WO 99/03854	01/28/99	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	* EP 0 564 409 [in German; English claims equivalent in AU-B-35694/93]	10/06/93	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AO	* AU-B-35694/93 [English claims corresponding to EP 0 546 409]	10/07/93	Australia			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Cohen, Residence in General Surgery, Homepage of the Washington University School of Medicine, Dept. of Surgery (1997, 1998).
	AS	* Cohen et al., "Inhibition of Medullary Thyroid Carcinoma Cell Proliferation and RET Phosphorylation by Tyrosine Kinase Inhibitors", <i>Surgery</i> , Vol. 132, No. 6, pp. 960-968 (2002).
	AT	Eng, "Biology of Neoplasia. RET Proto-Oncogene in the Development of Human Cancer", <i>J Clin Oncol</i> , Vol. 17, No. 1, pp. 380-393 (1999).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32586A  
APPLICATION NO.  
10/521,929  
APPLICANT  
OHTSURU ET AL.  
FILING DATE  
AUGUST 5, 2005

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Fagin, "Perspective: Lessons Learned from Molecular Genetic Studies of Thyroid Cancer--Insights into Pathogenesis and Tumor-specific Therapeutic Targets", <i>Endocrinology</i> , Vol. 143, No. 6, pp. 2025-2028 (2002).
	DB	Frasca et al., "Tyrosine Kinase Inhibitor STI571 Enhances Thyroid Cancer Cell Motile Response to Hepatocyte Growth Factor", <i>Oncogene</i> , Vol. 20, No. 29, pp. 3845-3856 (2001).
	DC	* Joensuu and Dimitrijevic, "Tyrosine Kinase Inhibitor Imatinib (STI571) as an Anticancer Agent for Solid Tumours", <i>Ann Med</i> , Vol. 33, No. 7, pp. 451-455 (2001).
	DD	Loré, Talidis, Di Cairano and Renieri, "Multiple Endocrine Neoplasia Type 2 Syndromes May be Associated with Renal Malformations", <i>J Intern Med</i> , Vol. 250, No. 1, pp. 37-42 (2001).
	DE	Meric et al., "Expression Profile of Tyrosine Kinases in Breast Cancer", <i>Clin Cancer Res</i> , Vol. 8, No. 2, pp. 361-367 (2002).
	DF	* Podtcheko et al., "The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells", <i>J Clin Endocrinol Metab</i> , Vol. 88, No. 4, pp. 1889-1896 (2003).
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.